Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Jun
27
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
Jun
01
Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community
Apr
20
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
Jan
06
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
Nov
14
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
Sep
22
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
Jun
01
Life with MG & What I Wish For Everyone Who is Diagnosed
May
27
My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis
May
10
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
